Opinion|Videos|September 13, 2024
Overview of Long-term Follow-up from MonumenTAL-1
Focusing on the MonumenTAL-1 study, Mary Steinbach, APRN, provides clinical insights on nail, skin, and oral toxicities associated with talquetamab.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Focusing on long-term follow-up data from MonumenTAL-1, describe the unique toxicities seen with talquetamab, namely nail-related, skin-related, and oral-related toxicities.
Advertisement
Related to this article
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
2
COA Warns That Price Negotiation for Medicare Part B Drugs Threatens Community Oncology
3
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
4
Using Intrathecal Dendritic Cells for Leptomeningeal Disease From Breast Cancer
5